Wednesday, April 23, 2014

Aurinia names Stephen Zaruby as president & CEO

Aurinia names Stephen Zaruby as president & CEO

November 6, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:AUP) has appointed accomplished biotech and pharma executive, Stephen Zaruby, as president and CEO. Mr. Zaruby┬áhas a strong track record of strategic operations, sales and marketing, research and development, and general management success in the global biotechnology and pharmaceutical industries. Previously, he was president of Seattle-based ZymoGenetics, which was acquired by Bristol-Myers […]

Isotechnika officially changes name to Aurinia Pharma

Isotechnika officially changes name to Aurinia Pharma

October 22, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX-V:ISA) has officially changed its name to Aurinia Pharmaceuticals and its common shares will be posted for trading on a 50:1 consolidated basis on the TSX Venture Exchange at the opening tomorrow under the trading symbol, AUP. The consolidation will result in 12,373,589 shares outstanding. “In many respects, the new Aurinia just […]

Aurinia makes post-merger management changes

Aurinia makes post-merger management changes

October 22, 2013 by · Leave a Comment 

Tweet Aurinia Pharmaceuticals (TSX-V:ISA), formerly Isotechnika Pharma, unveiled a post-merger strategic restructuring, including senior management changes, designed to further position the company to successfully bring voclosporin to market as a therapy for lupus nephritis. Dr. Richard Glickman has been appointed executive chairman and acting CEO, succeeding Dr. Robert Foster, who moves to the post of […]

Isotechnika, Aurinia complete merger, financing

Isotechnika, Aurinia complete merger, financing

September 23, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and Aurinia Pharmaceuticals have completed their merger and will operate under the name, Aurinia Pharmaceuticals. The transaction was approved by shareholders on Aug. 15. In connection with the merger, the company has completed, subject to regulatory approval, a private placement of 133,333,332 units, consisting of one common share and one half […]

Isotechnika holders okay merger with Aurinia

Isotechnika holders okay merger with Aurinia

August 16, 2013 by · Leave a Comment 

Tweet Shareholders of Isotechnika Pharma (TSX:ISA) have approved a merger with closely-held Aurinia Pharmaceuticals to create a clinical-stage pharmaceutical company focused on the global nephrology market. The plan of arrangement will be affected by an exchange of Isotechnika shares for securities of Aurinia, resulting in a 65-35 post-merger ownership split between the shareholders of Isotechnika […]

Isotechnika sets meeting to vote on merger for Aug. 15

Isotechnika sets meeting to vote on merger for Aug. 15

July 25, 2013 by · Leave a Comment 

Tweet A meeting of Isotechnika Pharma (TSX:ISA) shareholders to consider a proposed merger with closely held Aurinia Pharmaceuticals will be held on Aug. 15. The boards of Isotechnika and Aurinia firmly support the proposed merger, which is designed to create a premier clinical stage pharmaceutical company focused on the global nephrology market. The merger is […]

Isotechnika further updates merger and financing plans

Isotechnika further updates merger and financing plans

June 27, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and privately-held Aurinia Pharmaceuticals have issued a further update about their proposed merger to create a premiere clinical-stage pharmaceutical company focused on the global nephrology market. Under the merger accord, Isotechnika will acquire 100% of Aurinia in a stock swap, resulting in a 65-35 post-merger ownership split between Isotechnika and Aurinia, […]

Isotechnika gets more funding for NICAM program

Isotechnika gets more funding for NICAM program

June 18, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX: ISA) has received additional funding from the National Research Council Industrial Research Assistance Program (NRC-IRAP) for its non-immunosuppressive cyclophilin antagonist molecules (NICAM) program. NRC-IRAP continues to play an instrumental role in networking the NICAM program with key global partners and previously assisted Isotechnika in late-stage screening of several NICAM compounds, including […]

Isotechnika updates investors on planned merger with Aurinia

Isotechnika updates investors on planned merger with Aurinia

April 17, 2013 by · Leave a Comment 

Tweet Isotechnika Pharma (TSX:ISA) and closely-held Aurinia Pharmaceuticals have updated investors on their proposed merger to create a global nephrology company. The companies have now executed a definitive tripartite agreement with ILJIN Life Science. Subject to the successful completion of the proposed merger, the combined company will re-acquire full rights to voclosporin for autoimmune indications, […]

Glickman swinging for the fence again in Isotechnika merger

Glickman swinging for the fence again in Isotechnika merger

February 19, 2013 by · Leave a Comment 

Tweet Richard Glickman is poised to hit another home run with the proposed merger of his closely-held Aurinia Pharmaceuticals and Isotechnika Pharma (TSX:ISA) to create a global nephrology leader. Dr. Glickman has a decades-long track record of successfully developing and selling pharmaceutical and biopharmaceutical companies. For example, in 2001, he co-founded Aspreva Pharmaceuticals which went […]

Next Page »

Google+